Children's Oncology Group

Quick facts

Phase 3 pipeline

• in vitro sensitivity-directed chemotherapy · Oncology
  In vitro sensitivity-directed chemotherapy selects chemotherapeutic agents based on the sensitivity of tumor cells tested in a laboratory setting.
• Lactobacillus plantarum strain 299 · Oncology / Immunology
  Lactobacillus plantarum strain 299 is a probiotic bacterium that modulates the gut microbiome and intestinal barrier function to support immune homeostasis.
• Lactobacillus plantarum strain 299v · Oncology; Immunology
  Lactobacillus plantarum strain 299v is a probiotic bacterium that modulates the gut microbiome and enhances intestinal barrier function and immune tolerance.
• supersaturated calcium phosphate rinse

Phase 2 pipeline

• hu14.18-IL2 fusion protein
• hu14.18-Interleukin-2 fusion protein

Phase 1 pipeline

• ATM Kinase Inhibitor AZD1390 · Oncology
  ATM kinase inhibitor
• cereport · Other
• ECTEINASCIDIN 743
• FACT Complex-targeting Curaxin CBL0137
• HER2 Specific CAR T Cell
• SC-PEG E. coli L-asparaginase

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Children's Oncology Group portfolio CI brief
• Children's Oncology Group pipeline updates RSS